Link H, Kurrle E, Frauer H M, Heil G, Heimpel H, Waller H D, Ostendorf P, Wilms K, Hoelzer D
Onkologie. 1986 Jun;9(3):135-8. doi: 10.1159/000215985.
175 patients with acute myeloid leukemia were treated between February 1980 and March 1985 with a TAD-induction therapy, three intensified consolidation cycles (COAP, COAP, AD), and a two-year mild maintenance therapy. The median age of the patients was 44 years, range 15-68 years. 62.3% of all patients attained complete remission and 13.7% partial remission. The median duration of remission was 10 months and the median survival time of patients in complete remission was 20 months. Patients older than 50 years had a higher early death rate (17.6) than younger patients (8.9%), but no difference was found in remission rates or in the median duration of remission and of survival. These results are in line with those of comparable studies.
1980年2月至1985年3月期间，175例急性髓系白血病患者接受了TAD诱导治疗、三个强化巩固周期（COAP、COAP、AD）以及为期两年的轻度维持治疗。患者的中位年龄为44岁，范围在15至68岁之间。所有患者中62.3%达到完全缓解，13.7%达到部分缓解。缓解的中位持续时间为10个月，完全缓解患者的中位生存时间为20个月。50岁以上患者的早期死亡率（17.6%）高于年轻患者（8.9%），但在缓解率、缓解的中位持续时间和生存方面未发现差异。这些结果与同类研究结果一致。
